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Abstract
Human blood outgrowth endothelial cells (hBOEC) may be useful delivery-cells for gene therapy.
hBOEC have high expansion capacity and stable phenotype. If incorporated into blood vessels,
hBOEC could release therapeutic agents directly into the blood stream. However, little is known
about lodging and homing of hBOEC in vivo. We examined the homing patterns of hBOEC in
mice, and explored extending cell-based FVIII gene therapy from mice to larger animals. hBOEC
were injected into NOD/SCID mice to determine where they localize, how localization changes
over time and if there were toxic effects on host organs. The presence of hBOEC in mouse organs
was determined by qPCR and immunofluorescence microscopy. hBOEC lodged most notably in
mouse lungs at 3 h, but by 24 h there were no differences between 9 organs. hBOEC longevity
was assessed up to 7 months in vivo. hBOEC expanded well and then plateaued in vivo. hBOEC
from older cultures expanded equally well in vivo as younger. hBOEC caused no noticeable organ
toxicity up to 3 days post-injection. When mice were pretreated with antibodies to E-selectin, P-
selectin or anti-α4 integrin prior to hBOEC injection, the number of hBOEC in lungs at 3h was
inhibited. Preliminary studies infusing hemophilic dogs with autologous canine BOEC over-
expressing FVIII (B-domain deleted) showed improvement in whole blood clotting times
(WBCT). In conclusion, the survivability, expandability and lack of toxicity of BOEC in vivo
indicate that they may be valuable host cells for gene therapy.
INTRODUCTION
Blood outgrowth endothelial cells (BOEC) are an attractive source of cells for repairing
vascular injuries (i.e. post- infarction), seeding of vessel grafts, and as carrier cells in gene
therapy. BOEC are mature endothelial cells that have been expanded from circulating
progenitor cells from adult blood (1). Their high expansion capacity in culture makes BOEC
well suited for auto-transplantation. In addition, their phenotype is quite stable. We
previously showed that human BOEC (hBOEC) transfected with factor VIII (FVIII) gene
released FVIII in vivo in mice over many months (2).
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In order to exploit the therapeutic potential of endothelial cells, it is necessary to understand
their natural history after injection: their lodging, organ distribution, migration and
expansion. Where cells lodge influences their efficacy as gene therapy agents since some
vascular beds provide better microenvironments for long term maintenance and
proliferation. Lodging is dependent both on physical factors (vessel structure, density, and
flow rate) and on differential expression of cell surface adhesion molecules. Chemo-tactic
agents may alter a cell′s final location.
Very few studies have looked at which cell surface molecules mediate homing of endothelial
cells or their progenitors to specific organs. Indeed, it is unclear whether endothelial cells
home to specific organs or simply land and expand in more conducive environments. Our
preliminary studies suggested that hBOEC injected in NOD/SCID mice localized primarily
in bone marrow and spleen (2). In the present study we focused on the distribution of
hBOEC over time in 9 organs, with special emphasis on lung, bone marrow and spleen. We
evaluated the effect of cell surface molecules (both on hBOEC and mouse vessel beds) on
hBOEC localization. hBOEC express variable amounts of the adhesion molecules: Vascular
cell adhesion molecule (VCAM) and E-selectin, but negligible amounts of P-selectin,
alpha-4 integrin and P-selectin glycoprotein ligand (PSGL1). The vascular beds of bone
marrow, spleen and lungs differentially express VCAM, E-selectin and P-selectin. All three
molecules are constitutively expressed in bone marrow (3)(4). Lung expresses all three
molecules in large vessels (5). Alpha-4 integrin has been detected on proliferating but not
quiescent endothelium (6). Histamine and LPS induce different organ specific effects on E-
selectin and P-selectin (7).
This paper provides preliminary data on BOEC growth characteristics and the molecules
which mediate their expansion in vivo. In addition, it extends our knowledge of cell-based
FVIII gene therapy from mice to larger animals.
MATERIALS AND METHODS
Mice
NOD/SCID mice (Jackson labs), bred in our SPF facilities, were 8-12 wk old at the time of
injection. All studies were done with the approval of the Institutional Animal Care and Use
Committee at the University of Minnesota.
hBOEC isolation and injection
Blood for hBOEC isolation was obtained from healthy donors (age 19-30) according to
ethical protocols at the University of Minnesota. hBOEC were isolated as described in (1).
hBOEC pooled from frozen and passed stocks of 4 donors (passage 5 or 6) were used for tail
vein injection. Each injection contained 4×105 hBOEC in 0.1 ml mouse saline or 8×105
hBOEC in 0.2 ml mouse saline. FACS analysis (1), of all experiments, ensured the
endothelial character of the hBOEC. Positive markers for endothelial cells included VE
cadherin and P1H12. The negative marker was CD14.
β2-microglobulin/PECAM (CD31) staining to detect human BOEC in mouse tissue
Frozen sections (5μ) were acetone fixed 10 minutes and stored at −80°C. For use, sections
were fixed with 4% PFA/PBS; blocked with 3 % BSA/PBS; stained 1h with rabbit anti-
human β2-microglobulin (1:200) (Accurate Chemicals) and rat anti-mouse CD31 (1:100)
(BD BiosciencesPharmingen); treated with secondary donkey anti-rabbit/TRITC (Jackson
Labs) and anti-rat /FITC for 30 min and counterstained with DAPI.
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Paraffinized sections (5μ) or frozen sections were stained with hematoxilin/eosin and
viewed for tissue integrity.
Mouse Blocking Experiments
NOD/SCID mice were tail-vein injected with 50 micrograms of azide-free rat anti-mouse
antibodies from BD Pharmingen: anti-α4 integrin IgG2a (clone R1-2), anti P-selectin IgG1
(clone RB40.34), anti E-selectin IgG2a (clone 10E 9.6), anti-VCAM IgG2a (clone 429),
anti-PSGL1 IgG1 (clone 2PH1), and saline, or normal rat IgG (Southern Biotech) 1 h prior
to injection of 8×105 BOEC/mouse.
BOEC blocking experiments
8×105 hBOEC/mouse were pretreated with 10 micrograms of azide-free mouse anti-human
antibody for 30 minutes and rinsed prior to tail vein injection. Mouse anti-human antibodies
included: anti-α4 integrin IgG1 (BU49) (Calbiochem), anti-P-Selectin IgG1 (Clone AK4,
BD Pharmingen), anti-VCAM IgG1 (HAE-2Z, Santa Cruz), or anti-VCAM IgG1(1G11,
Beckman), anti-PSGL1 (3E2.25.5, Beckman), anti-E-selectin IgG1 (Hae-1f, Ancell) and
normal mouse IgG (Southern Biotech).
Development and analysis of canine FVIII-expression in canine BOEC (cBOEC)
cBOEC from three Hemophilia A dogs (E64, D28 and H17, Chapel Hill HA colony, NC) (8)
were isolated according to protocols (1). cBOEC expressed normal endothelial markers:
PECAM, von Willebrand factor (vWF) and LDL. All procedures were approved by the
University of North Carolina Institutional Animal Care and Use Committee.
cBOEC were transduced with retroviral particles containing MIRG/cFVIII (constructed
from pBK-CMV-FVIIIcDNAbdd; a gift from Dr. Lillicrap, Queen’s University, Canada).
Positive cFVIII producing cBOEC (cBOEC/FVIII) (named tdH64, tdH28 and tdH17) were
selected by sterile FACS sorting. cFVIII concentration and activity produced by cBOEC/
FVIII were detected by IMUBIND FVIII ELISA kit (American Diagnostic) and Coamatic
Factor VIII Kit (Chromogenix) respectively. cBOEC/FVIII expressed endothelial markers
and took up LDL. The copy number of transgene in cBOEC/cFVIII was examined by real-
time qPCR.
Infusion
Three hemophilia A dogs (E64, D28 and H17) in Chapel Hill HA colony were infused with
autologous cBOEC/FVIII. Dog ages at the start of infusions were E64 (3.6 years), D28 (5.6
years), and H17 (1.8 years). For each infusion, 65 to 136 million viable autologous cBOEC/
FVIII cells per 150 ml of saline were infused into each hemophilia A dog through the
cephalic vein. Blood samples were collected periodically for monitoring WBCT,
hematological parameters and liver and kidney function.
Whole Blood Clotting Assay
WBCT were performed by a two-tube procedure at 28°C. One ml of whole blood was
collected and distributed equally into two siliconized tubes (Becton-Dickinson). The first
tube was tilted every 30 sec. After a clot formed, the second tube was tilted and observed
every 30 sec. The endpoint was the clotting time of the second tube.
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Real-time DNA Quantitative PCR
Genomic DNA from BOEC and from each animal organ was isolated immediately using
DNeasy Tissue Kit (Qiagen) according to the manufacturer′s protocol. Genomic DNA real-
time qPCR was performed using I Cycler (Bio-Rad) for the quantitation of hBOEC in each
mouse organ. Primers and 3′ labeled fluorescence FAM-probe for human β2-microglobulin
were designed to amplify human genomic DNA specifically. Sequences are as follow: sense
primer -5’-GCT GGA TTG GTA TCT GAG GCT AG-3’; antisense primer-5’- GCT GTT
CCT ACC CAT GAA TAC AT-3’; 5’-FAM-AAG GGC TTG TTC CTG CTG GGT AGC
TCT AAA C-TAMRA-3’. The kit of TaqMan Rodent GAPDH Control Reagents that
contains universal primers and fluorescence VIC- probe (Applied Systems) were used for
internal control for amplifying both human and mouse genomic DNA. Standard curves were
set up by serially diluting human genomic DNA in mouse genomic DNA. Each real-time
PCR reaction contained 500ng of genomic DNA, 200nM of each primer, 150nM of each
probe and 1× of iQ supermix (Bio-Rad Laboratories). The PCR condition was as follows:
Denaturation at 95°C for 5 minutes following by 60 cycles of two-step PCR (95°C for 30
seconds and 60°C for 30 seconds). Modified Ct (Threshold Cycle) value was calculated by
dividing the Ct of hB2M with that of GAPDH. Percent of human cells in each mouse organ
was calculated based on the standard curve. Sequences of probes and primers for the copy
number of transgene in cBOEC/cFVIII and the quantity of cBOEC/cFVIII in canine organs
were as follow: Sense-5’-CAT CGG CGT GCA GTG CTT-3’; Antisense-GGG CAT GGC
GGA CTT G-3’; Probe-5’FAM-CCG CTA CCA CAT GAA GC-TAMRA-3’. Serial dilution
of cBOEC/FVIII genomic DNA in cBOEC genomic DNA was used as a standard curve.
Statistics
Two-way Analysis of Variance (ANOVA) model was used to investigate effects of time
periods and organ types on percentage of hBOEC in mice. All multiple comparison p-values
were adjusted by the Tukey-Kramer procedure (9), and adjusted p-values < 0.05 were
ascertained to be statistically significant. All statistical analyses were performed using SAS
9.0 (9). Since the effect of time periods on percentage of hBOEC differed between different
organs (F test p-value = .015), we additionally fit separate one-way ANOVA models for
each organ to investigate organ-specific time effects.
RESULTS
Understanding the natural history of hBOEC in their NOD/SCID hosts is an important
antecedent to properly designing gene therapy studies. We must know which organs are
amenable to initial seeding, whether the same organs are conducive to hBOEC expansion,
and whether hBOEC growth plateaus.
We concentrated on 4 questions. 1) What is the relative distribution of hBOEC in 9 organs at
3h and 24h post injection? 2) Are toxic effects present at early time points? 3) How much do
hBOEC expand in various organs at 2 wks, 2 months and 4 months? 4) Does the age of
hBOEC at the time of injection affect expansion capacity?
hBOEC were visible in all tested organs (brain, gut, heart, kidney, liver, lung, ovaries/testes,
spleen and bone marrow) by their positive staining for human β2-microglobulin and
characteristic large size. Transplanted cells were present as single cells or trains of cells, not
clumps, in all tissue samples. A number of large β2-microglobulin positive hBOEC were
noted in capillaries, and larger vessels, but rarely in alveoli and bronchi in lungs of all
animals after 3h and much fewer at 24h and 3 days (Fig1). Stained cells were found mostly
but not exclusively in peribronchial areas. Numbers of cells varied greatly from animal to
animal and from section to section.
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The amount of hBOEC in 9 mouse organs at 3h and 24h post tail vein injection was
determined by real-time quantitative polymerase chain reaction (qPCR) of hBOEC per total
cells per organ (Fig 2). Data were analyzed by ANOVA and t-test. 3h post-injection, lung
had significantly higher percentage of hBOEC than any other organs (all Tukey-Kramer
adjusted p-values < 0.0001), whereas at 24h there was no significant difference between
organs. Percentage of hBOEC decreased significantly from 3h to 24h in gut, heart, liver,
lung, spleen and bone marrow (all t-test p-values < 0.05), and decreased with marginal
significance in kidney and testis. The decrease in hBOEC in most organs at 24h suggests
that hBOEC are either dislodged, or die and are cleared.
Two sets of tissues were examined for toxicity: 3h and 24h (frozen sections), and 3h and 3
days (paraffinized sections) (8 mice per group). No significant difference in morphology
was observed between animals injected with hBOEC versus control animals that received
only saline at 3h, 24h and 3d. In both experimental groups, severe lymphocyte depletion was
noticed in all animals (this is characteristic for NOD/SCID mice). Dr. Carlson (veterinary
diagnostic lab, University of Minnesota) independently confirmed that there was no
significant difference between the control group and hBOEC recipients. These results extend
our preliminary studies at 9d, 28d and 156d (2). No thrombosis, occlusions or infarcts were
evident in either that preliminary study or the present study.
Expansion of hBOEC in 9 different organs was monitored at 2 wks, 2 months, and 4 months
(Fig 3). Expansion capacity was determined from percent of hBOEC/total cells/organ at
different time points. ANOVA was used to analyze overall expansion, as well as time and
organ effects for individual organs. Averaged over organs, percentage of hBOEC
significantly decreased from 2 wks to 2 months (p=.003), while significant increase was
seen at 4 months compared to both 2 wks and 2 months (p=.001). For all organs but heart
and kidney, there was significant increase in percentage of human cells from 2 wks to 4
months. In addition, all organs except spleen, had significantly increased percentage of
human cell from 2 months to 4 months.
Average increase from two wks to four months was 6-fold for bone marrow and spleen, 3-
fold for liver and testis/ovary, and 1.5-2-fold for other organs. This indicates that many
organs provide a suitable environment for hBOEC expansion. Brain, kidney and liver
showed significant decrease from 2 wks to 2 months. The drop in hBOEC between 2 wks
and 2 months might indicate cell death followed by bursts of expansion of remaining
hBOEC. Another experiment monitored expansion of hBOEC in bone marrow and spleen
out to 7 months. hBOEC levels plateaued between months 4 and 5 (not shown). There was
no significant difference in mortality rate between injected and uninjected mice at 7 months.
Conceivably, the age of hBOEC at the time of injection might affect their ability to expand
and survive. hBOEC were tail vein injected at passage 5, 10 and 15, and analyzed 6 months
later in bone marrow, spleen and lung (Fig 4). There was no significant difference in vivo
between earlier and later passages of hBOEC. hBOEC from passage 15 grew and survived
in vivo as well as passages 5 or 10 from the same donor. FACS analysis showed that VCAM
and VE-cadherin expression remained stable through passage 10, but VE-cadherin
expression declined in some donors by passage 15 (not shown).
Many hBOEC initially lodge in lungs at three hours. We wanted to know which cell
adhesion molecules might be involved in lodging and whether we could decrease lodging in
lungs and simultaneously increase lodging in other organs, such as bone marrow or spleen,
by pre-treating either the mice or hBOEC with antibodies to cell adhesion molecules.
Mice were pretreated with antibodies to E-selectin, P-selectin or α4 integrin for 1h prior to
tail vein injection of hBOEC (two experiments). Organs were harvested at 3-4 h from lung,
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bone marrow, and spleen (Fig 5). Anti-E-selectin, anti-P-selectin or anti-α4 integrin
antibodies inhibited mouse tissue (P<.01 versus controls), so that fewer hBOEC lodged in
the lungs (Fig 5a). Bone marrow lodging was not significantly inhibited with anti-α4
integrin (Fig 5b). Studies were inconclusive for P- or E-selectin in bone marrow and for all 3
antibodies in spleen. Only 1 set of experiments had mice pretreated with anti-VCAM or anti
PSGL-1 (not shown). Anti-VCAM did not inhibit lodging in lung, bone marrow or spleen.
PSGL-1 blocked lodging in spleen P < 0.01 versus either saline or control antibody and lung
(P-value 0.01 versus saline, but not control antibody).
FACS analysis of unstimulated hBOEC showed that they express variable amounts of
surface VCAM (32% +/− 27%) and E-selectin (11% +/− 15%), and less than 10% P-
selectin, α4-integrin and PSGL1-1. 90% of TNFα stimulated hBOEC expressed VCAM.
These results suggested that anti-VCAM treatment might be the most effective hBOEC
inhibitor, but this would depend on the activation state of the hBOEC. When unstimulated
hBOEC were pretreated with antibodies to VCAM, α4-integrin or P-selectin for 30 minutes
prior to tail vein injection, there was no significant inhibition of homing to lung, bone
marrow or spleen (not shown).
These results suggest that E-selectin, P-selectin and α4 integrin on lung vasculature may be
involved in hBOEC lodging. Since inhibition was partial, it is likely that mechanical forces
are also involved in lodging. It is also likely that lung α4 integrin is binding to some other
ligand than VCAM, since anti-VCAM pretreatment of hBOEC did not inhibit lodging.
The canine model of hemophilia has been widely used for developing and evaluating gene
therapies (10). We chose the canine model to evaluate the use of canine BOEC (cBOEC) as
an autologous cell-based gene therapy for hemophilia A. cBOEC were isolated from three
Hemophilia A dogs. The cBOEC were manipulated to over-express canine FVIII. Canine
FVIII producing cBOEC lines (tdE64, tdD28 and tdH17) showed standard endothelial
markers and LDL uptake that were the same as those of their parental cBOEC (data not
shown). FVIII production from 1 million cells in 10 ml culture medium of cBOEC/FVIII
was ~250ng/ml. Transgene copy number per cell of cBOEC/FVIII was 4.6-5.3.
Autologous cBOEC/FVIII cells were infused into three hemophilia A dogs. Whole blood
clotting times (WBCT) in the three dogs were clearly improved after infusions (Fig. 6).
Whereas baseline WBCT was >60 minutes in each of these dogs, post infusion WBCT
repeatedly dipped below 40 minutes, and sometimes below 30 minutes. (The historical range
for hemophilia A dogs is 40 to >60 minutes). After the initial drop in WBCT at 2-14 days,
the WBCT rose in all 3 dogs, before dropping again. This may indicate that infused cBOEC/
FVIII cell numbers (and FVIII expression) decline before rebounding. Although this
improvement did not meet the normal range (8 to 12 minutes), it is important to note that the
improvement in WBCT lasted many months. As a control, we infused non-transfected
canine BOEC into one hemophilia A dog. WBCT in the control did not decrease at 1hr, 4 hr
or 24hr post infusion (not shown). Also noteworthy is the dearth of bleeding incidents in
these BOEC/FVIII treated dogs (1 per year or less), whereas hemophilia A dogs have, on
average, six bleeding incidents per year. Cell infusions had no dramatic effect on either the
animals’ hematological parameters or liver and kidney functions (not shown). However,
infusions tended to be associated with mild transient thrombocytopenia.
Distribution of autologous cBOEC/FVIII in 11 organs was examined by qPCR in 2 dogs:
dog E64 (430d after first infusion) and dog H17 (160d after first infusion). Most of the
cBOEC/FVIII homed to liver in both dogs (0.2% and 0.4% of liver cells respectively) after
the infusions, with heart retaining the second highest levels (0.02% and 0.155%
respectively). Further studies are needed to corroborate these preliminary findings.
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We have shown that hBOEC lodge in many mouse organs, most notably lungs, within 3h of
tail vein injection, and that the number of hBOEC in lungs and other organs decreases
significantly by 24h. There were no significant signs of toxicity in the hosts at 3h, 24 h or 3
days post injection. hBOEC expanded in all 9 organs examined over 4 months. hBOEC
populations reached plateaus in host organs. hBOEC from older cell culture (passage 15)
were equally able as younger hBOEC to expand in vivo. The survivability, expandability and
lack of toxicity of hBOEC indicate that they are a useful tool for gene therapy.
In mice, bone marrow and spleen consistently displayed high expansion capacity for
hBOEC. By contrast, hBOEC initially lodged in lung in much higher numbers than in bone
marrow or spleen but lung had lower expansion capacity from 2 wks to 4 month. The
number of hBOEC can be the result of lodging, cell division, migration, or death. A recent
study of porcine BOEC 24h post injection also showed a wide distribution in mouse tissues.
The highest concentrations were in liver and lung (11).
The number of hBOEC detected in the nine different organs was a small fraction of the total
injected. From the literature it appears that BOEC or progenitor cell lodging is normally low
in healthy organs (12) (13). Recipient NK cells or macrophages may deplete the population
(14). E-selectin on bone marrow may promote apoptosis of mobilized CD34 + cells (3).
We began studies on cell surface molecules that might be involved in early lodging and
homing of hBOEC. We focused on molecules, such as α4 integrin, E-selectin, P-selectin,
VCAM and PSGL-1 that have been implicated in homing of stem cells or EPC′s.
Pretreatment of mice with antibodies to E-selectin, P-selectin, or α4 integrin inhibited
lodging of hBOEC in the lung at 3h. Since inhibition was only partial, future studies should
determine whether other molecules affect lodging and which ligands on hBOEC bind to lung
endothelium. Known ligands for α4/β1 integrin include VCAM, the HepII/IIICS domain of
fibronectin (15), and propolypeptide of vWF (16). Ligand binding of α4 integrin is complex
and therefore may be difficult to detect and inhibit in vivo. α4 integrin is expressed on
proliferating but not quiescent endothelial cells (6) and exists in both low affinity and high
affinity states (17).
Homing studies with hematopoietic progenitor cells envision α4 integrin on these cells and
E-or P-selectin or VCAM on host endothelium (18). By contrast, we suggest that α4 integrin
on host lung endothelium binds to some ligand on hBOEC. Since pretreatment of hBOEC
with antibodies to VCAM, had no effect on lodging of hBOEC in lungs, it is possible that
either the HepII/IIICS domain of fibronectin or vWF is forming a bridge between α4
integrin on lung endothelium and hBOEC.
The cell surface molecules that control BOEC lodging in uninjured vasculature may differ
from homing to injured vasculature. Hind limb ischemia experiments may provide insights
into how BOEC might respond to activated blood vessels. Homing capacity of endothelial
cells and EPC′s to ischemic hind limb was altered by several antibodies. Yang (19)
expanded human Cd133 + cord blood cells into differentiated endothelial cells and tail vein
injected these into nude mice, where they incorporated into blood vessels in ischemic
hindlimb. Incorporation was decreased by pretreating endothelial cells with anti-PSGL-1.
Duan (20) found that VCAM was upregulated in vessel endothelium of ischemic mouse
tissue. Recovery of hind limb blood flow with EPC′s was inhibited when these cells were
pretreated with antibodies to α4 integrin.
Our preliminary studies of autologous cBOEC/FVIII infused into hemophilia A dogs
resulted in modest decreases in clotting times that were sustained up to 4 months. Although
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these decreases never reached normal levels, improvements of the method are readily
envisioned. Dogs were infused with ~1/10 the BOEC number/kg of host as in the mice.
Increasing cBOEC/FVIII number10-fold in dogs would probably increase the amount of
FVIII delivered, thus improving clotting time. Treatment might also be improved with
young puppies since host size would be smaller, thus decreasing the number of cBOEC/
FVIII needed; and the natural growth of pup blood vessels might provide more in vivo sites
for cBOEC/FVIII incorporation and expansion. Modifications in the promoter region of the
FVIII expression vector could improve efficiency of expression, and modifications in the 3′
untranslated region could increase RNA stability. Modifications of FVIII at charged amino
acid residues could increase protein stability (21).
Although there has been some success with viral vector infusion therapy in hemophilia (22),
BOEC based gene therapy offers several advantages. Since the FVIII gene is only
introduced ex vivo, the chance of protein synthesis of FVIII increases, whereas the chance of
unexpected effects decreases; no virus is introduced into other cell types in vivo. Unexpected
effects might be further diminished by implanting FVIII expressing BOEC subcutaneously
in a Matrigel™ scaffold (23). BOEC also have an advantage over hematopoietic stem cell
based gene therapy because BOEC will not differentiate into a wide variety of cell types
with unpredictable outcomes.
BOEC are a potential resource for repopulating wounded endothelium and a potential host
cell for gene therapy. Endothelial cells are particularly valuable as hosts because they could
release the therapeutic gene product directly into the blood stream. These in vivo studies
provide further evidence that BOEC have growth characteristics and lack of toxicity that
would make them suitable as carrier cells for gene therapy.
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Fig 1. hBOEC localization in lung tissue
β2-microglobulin positive hBOEC are present in lung tissue at 3h post tail vein injection.
(A) hBOEC injected mice, 15× magnification; (B) Artery, 60× magnification; (C) Vein, 60×
magnification; (D) Capillaries, 60× magnification. (E) hBOEC within capillary, 60×
magnification. β2-microglobulin = red; PECAM = green; β2-microglobulin-PECAM
overlap = yellow. Dapi nuclei = blue.
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Fig 2. Distribution of total hBOEC in 9 mouse organs
4×105 hBOEC /mouse were tail-vein injected into NOD/SCID mice (8 mice per time point).
Organs were harvested at 3h and 24h and analyzed by real-time qPCR. Data represents %
hBOEC per total cells per organ. Error bars represent standard deviations. P-value is for
lung versus other organs. One experiment.
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Fig 3. hBOEC expansion in 9 organs at 2 wks, 2 months and 4 months
8×105 hBOEC /mouse/day were tail-vein injected into NOD/SCID mice on 3 consecutive
days. Organs were harvested at 2 wks, 2 months, and 4 months and analyzed by real-time
qPCR (12-15 mice per group). Data represents % hBOEC per total cells per organ. Error
bars represent S.D. P-values are for 2 wks versus 4 months. One experiment.
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Fig 4. Expansion capacity of hBOEC of different ages
8×105 hBOEC /mouse/day were tail-vein injected into NOD/SCID mice on 3 consecutive
days. hBOEC were from passage 5, 10 or 15 at the time of injection. Organs were harvested
6 months after injection (n=10 per group). Error bars represent S.D. One experiment. Data
represents % hBOEC per total cells per organ.
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Fig 5. Effect of treating mice with antibodies prior to hBOEC injection
NOD/SCID mice were tail-vein injected with 50 μgrams anti-α4 integrin (Clone R1-2), anti-
P-selectin (Clone RB40.34) and anti-E-selectin (Clone 10E 9.6) rat anti-mouse antibodies,
normal rat IgG or with saline, 1 h prior to injection of 8×105 BOEC /mouse. Organs were
harvested 3 hours later (8 mice per group). Error bars represent S.D. 5A) Lung: **
P<0.01for each test antibody compared to saline or control antibody. 5B) Bone Marrow: no
significant changes. 5C) Spleen: anti-α4 integrin and anti E-selectin had *P<0.1 versus
controls. Data confirmed by second experiment (not shown).
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Fig 6. Whole blood clotting time following infusion of cBOEC/FVIII cells
Autologous cBOEC/FVIII cells were infused into three hemophilia A dogs: (A) E64, (B)
D28 and (C) H17. One or two infusions (depending on cell amount) were given for 3
consecutive days to each dog. This was repeated several months later. Dog H17 received
two sets of infusions, whereas E64 and D28 each received three sets. White arrows show
infusion date and total number of cells infused. Clotting times were measured for a
maximum of 60 min. Pre-infusion WBCT were >60 for all 3 dogs. Dark arrows indicate
treatment for acute bleeds after altercations. There are 46 time points for E64, 40 for D28
and 24 for H17.
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